Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omega-3 fatty acids for CRC prevention in Lynch Syndrome
NCT03831698Phase 2Unknown
- Sponsor
- University of Kansas Medical Center
- Start
- Feb 2019
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of omega-3-acid triglycerides in colorectal cancer (CRC), sponsored by University of Kansas Medical Center. Primary endpoint: Retention rate of participants at 12 months. Status: unknown.
02
Drugs
omega-3-acid triglycerides
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03831698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03831698.